“Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool” (ClinicalTrials.gov Identifier: NCT01699711). The gene discussed is APP; the disease is Dravet syndrome.